2025

Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma

Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh, discussed the design and potential clinical effects of the phase 3 SUPRAME trial (NCT06743126), which is evaluating the efficacy of IMA203, a T-cell receptor–transduced T-cell therapy (TCR-T), vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Read More

Making Sense of Melanoma Adjuvant Treatment in the Absence of OS Data

We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.

Read More
MRV News
Melanoma News
Archive
Menu